RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aurinia Pharmaceuticals Stock

Aurinia Pharmaceuticals Revenue 2024

Aurinia Pharmaceuticals Revenue

238.79 M USD

Ticker

AUPH

ISIN

CA05156V1022

WKN

A1W7D4

In 2024, Aurinia Pharmaceuticals's sales reached 238.79 M USD, a 36.05% difference from the 175.51 M USD sales recorded in the previous year.

The Aurinia Pharmaceuticals Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e504.4331,99
2028e470.0534,33
2027e423.3638,12
2026e350.0346,10
2025e283.8556,85
2024e238.7967,58
2023175.5191,94
202213495,82
202145.697,59
202050.1322,09
20190.353788,33
20180.532273,00
20170.4100,00
20160.2100,00
20150.2100,00
20140.366,67
20131100,00
20126.1100,00
2011190,00
20103.3100,00
20092.395,65
20084.445,45
20072.254,55
20063.683,33
20051.127,27
20041.225,00

Aurinia Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aurinia Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aurinia Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aurinia Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aurinia Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aurinia Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aurinia Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aurinia Pharmaceuticals’s growth potential.

Aurinia Pharmaceuticals Revenue, EBIT and net profit per share

DateAurinia Pharmaceuticals RevenueAurinia Pharmaceuticals EBITAurinia Pharmaceuticals Net Income
2029e504.43 M undefined0 undefined215.86 M undefined
2028e470.05 M undefined250.38 M undefined192.89 M undefined
2027e423.36 M undefined213.8 M undefined172.83 M undefined
2026e350.03 M undefined127.44 M undefined111.43 M undefined
2025e283.85 M undefined65.13 M undefined60.77 M undefined
2024e238.79 M undefined12.85 M undefined7.05 M undefined
2023175.51 M undefined-91.69 M undefined-78.02 M undefined
2022134 M undefined-111.5 M undefined-108.2 M undefined
202145.6 M undefined-180.7 M undefined-181 M undefined
202050.1 M undefined-104.3 M undefined-102.7 M undefined
2019300,000 undefined-90.9 M undefined-88.4 M undefined
2018500,000 undefined-56.4 M undefined-64.1 M undefined
2017400,000 undefined-47.6 M undefined-70.8 M undefined
2016200,000 undefined-24.4 M undefined-23.3 M undefined
2015200,000 undefined-23.9 M undefined-18.6 M undefined
2014300,000 undefined-18.4 M undefined-19.4 M undefined
20131 M undefined-4.1 M undefined-2.7 M undefined
20126.1 M undefined-4.1 M undefined-9.7 M undefined
20111 M undefined-6.6 M undefined-2.5 M undefined
20103.3 M undefined-5.1 M undefined-3.7 M undefined
20092.3 M undefined-9.2 M undefined-7 M undefined
20084.4 M undefined-17.9 M undefined-18.1 M undefined
20072.2 M undefined-33.1 M undefined-31.2 M undefined
20063.6 M undefined-24.4 M undefined-23.5 M undefined
20051.1 M undefined-28.9 M undefined-27.9 M undefined
20041.2 M undefined-20.7 M undefined-20.9 M undefined

Aurinia Pharmaceuticals stock margins

The Aurinia Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aurinia Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aurinia Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aurinia Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Aurinia Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aurinia Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aurinia Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aurinia Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aurinia Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aurinia Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aurinia Pharmaceuticals Margin History

Aurinia Pharmaceuticals Gross marginAurinia Pharmaceuticals Profit marginAurinia Pharmaceuticals EBIT marginAurinia Pharmaceuticals Profit margin
2029e91.94 %0 %42.79 %
2028e91.94 %53.27 %41.04 %
2027e91.94 %50.5 %40.82 %
2026e91.94 %36.41 %31.83 %
2025e91.94 %22.95 %21.41 %
2024e91.94 %5.38 %2.95 %
202391.94 %-52.24 %-44.45 %
202295.82 %-83.21 %-80.75 %
202197.59 %-396.27 %-396.93 %
202091.94 %-208.18 %-204.99 %
201991.94 %-30,300 %-29,466.67 %
201891.94 %-11,280 %-12,820 %
2017100 %-11,900 %-17,700 %
2016100 %-12,200 %-11,650 %
2015100 %-11,950 %-9,300 %
201466.67 %-6,133.33 %-6,466.67 %
2013100 %-410 %-270 %
2012100 %-67.21 %-159.02 %
201190 %-660 %-250 %
2010100 %-154.55 %-112.12 %
200995.65 %-400 %-304.35 %
200845.45 %-406.82 %-411.36 %
200754.55 %-1,504.55 %-1,418.18 %
200683.33 %-677.78 %-652.78 %
200527.27 %-2,627.27 %-2,536.36 %
200425 %-1,725 %-1,741.67 %

Aurinia Pharmaceuticals Aktienanalyse

What does Aurinia Pharmaceuticals do?

Aurinia Pharmaceuticals Inc is a biopharmaceutical company that was founded in Canada in 1993. The company specializes in developing therapy options for autoimmune diseases, particularly the treatment of Lupus Nephritis, a condition where the immune system mistakenly attacks the body's own cells and damages the kidneys. Aurinia specializes in the field of biologic medications, which are based on proteins that naturally occur in the human body. These medications are used to modulate the immune system and "suppress" specific cells that trigger autoimmune diseases. Aurinia's main product is Voclosporin, an orally administered drug specifically developed for the treatment of Lupus Nephritis. Clinical trials have shown promising results, and Voclosporin received approval from the US FDA in 2020. Voclosporin is now successfully used in several countries worldwide. Aurinia also conducts research and development in other areas of autoimmune diseases. Another potential application is the treatment of Vogt-Koyanagi-Harada disease, a rare eye condition also attributed to autoimmune diseases. Aurinia's business model is based on developing new therapies that address the medical needs of patients with autoimmune diseases. The company focuses on close collaboration with medical professionals, patients and their families, as well as regulatory authorities. Aurinia has also formed partnerships with other companies and non-profit organizations to support its research and development and enhance access to its products in different countries. Aurinia's success relies on the extensive experience and expertise of its employees in biotechnological research, development and manufacturing of biologic medications, as well as its close partnerships with world-leading physicians in the field of autoimmune diseases. The company is committed to constantly improving the quality of its products and services to enhance patients' quality of life and effectively treat their disease. Overall, Aurinia Pharmaceuticals is a company dedicated to developing innovative therapies for autoimmune diseases, particularly for the treatment of Lupus Nephritis. The company strives to meet the medical needs of patients, their families, and medical professionals while also improving the entire ecosystem of medical care in this field. Aurinia's goal is to provide patients with better and more effective therapies and treatments to improve their health and well-being. Aurinia Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Aurinia Pharmaceuticals's Sales Figures

The sales figures of Aurinia Pharmaceuticals originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Aurinia Pharmaceuticals’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Aurinia Pharmaceuticals's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Aurinia Pharmaceuticals’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Aurinia Pharmaceuticals stock

How much revenue did Aurinia Pharmaceuticals generate this year?

Aurinia Pharmaceuticals has achieved a revenue of 238.79 M USD this year.

How much was the turnover of the company Aurinia Pharmaceuticals compared to the previous year?

The revenue of Aurinia Pharmaceuticals has increased by 36.05% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Aurinia Pharmaceuticals?

The revenue of Aurinia Pharmaceuticals is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Aurinia Pharmaceuticals measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Aurinia Pharmaceuticals so important for investors?

The revenue of Aurinia Pharmaceuticals is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Aurinia Pharmaceuticals pay?

Over the past 12 months, Aurinia Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aurinia Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Aurinia Pharmaceuticals?

The current dividend yield of Aurinia Pharmaceuticals is .

When does Aurinia Pharmaceuticals pay dividends?

Aurinia Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Aurinia Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aurinia Pharmaceuticals located?

Aurinia Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aurinia Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aurinia Pharmaceuticals from 9/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/8/2024.

When did Aurinia Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/8/2024.

What was the dividend of Aurinia Pharmaceuticals in the year 2023?

In the year 2023, Aurinia Pharmaceuticals distributed 0 USD as dividends.

In which currency does Aurinia Pharmaceuticals pay out the dividend?

The dividends of Aurinia Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aurinia Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aurinia Pharmaceuticals

Our stock analysis for Aurinia Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurinia Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.